A. Nagrial

440TiP A phase II/III trial of a PD-1/VEGF bispecific antibody (PF-08634404) in combination with chemotherapy in first-line for extensive-stage small cell lung cancer (Symbiotic-Lung-04)

Federico Cappuzzo, Eric Scott Schaefer, Yuta Yamanaka, B.A. Chan et autres

PF-08634404 is a fully human immunoglobulin G4 bispecific antibody that simultaneously targets PD-1 and VEGF. Phase II studies have shown promising efficacy and manageable safety with PF-08634404 as a monotherapy and with chemotherapy in first-line non-small cell lung cancer. This study will …

us, jp, au, cn, fr, de, es, it (code pays fourni par la source)

P1.17.62 Real-World Insights on Treatment Patterns and Outcomes in ROS1 NSCLC: An Australian Multicenter Study (AURORA)

M. Alexander, M. Itchins, Steven C-H Kao, A. Nagrial et autres

au, gb, us (code pays fourni par la source)

936P A phase I dose escalation trial of IKS014, a HER2-targeting antibody drug conjugate (ADC), in participants with advanced HER2+ solid tumors

Malaka Ameratunga, A. Nagrial, Peter K. H. Lau, Khanh-Van T. Bui et autres

au (code pays fourni par la source)

623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12

F.P. Lin, A. Mersiades, J. Lee, W. Xu et autres

au (code pays fourni par la source)

282P Nivolumab and ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancer

Oliver Klein, Matteo Salvatore Carlino, Michelle Poirier Brown, Samuel John Harris et autres

au, gb, nz (code pays fourni par la source)

471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC

M. Crumbaker, M. Carlino, Reina Hui, A. Mersiades et autres

au (code pays fourni par la source)